Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Antidote for Valproic Acid Toxicity: a New Indication for Meropenem Antibiotic. A Randomized Placebo-controlled Trial

NCT04671589 is registered in ClinicalTrials.gov with Mabaret Al-Asafara Hospitals as lead sponsor.

NCT NCT04671589
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04671589 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Antidote for Valproic Acid Toxicity: a New Indication for Meropenem Antibiotic. A Randomized Placebo-controlled Trial
Lead sponsor
Mabaret Al-Asafara Hospitals
Phase
Phase 4
Overall status
Unknown status
Start date
June 30, 2021
Completion date
December 31, 2022
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug toxicity